Endoscopic Ultrasound Guided Fine Needle Biopsy (EUS-FNB-SC) Using a Novel Fork Needle
| Status: | Completed |
|---|---|
| Conditions: | Cancer, Cancer, Pancreatic Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - 100 |
| Updated: | 3/30/2019 |
| Start Date: | March 2016 |
| End Date: | November 16, 2018 |
Pilot-Feasibility Trial of EUS Guided Pancreas Fine Needle Core Biopsy for Whole Exome Sequencing and Genomic Profiling
This is a clinical trial to compare two needles used in biopsy techniques to acquire tissue
from pancreatic cancer. The hypothesis is that the tissue yield, as measured by tumor DNA and
cellular material is superior for Flexible Needle Biopsy (FNB) compared with conventional
Fine Needle Aspiration (FNA). Specifically, FNB will increase the proportion of cases in
which sufficient DNA is obtained to allow genomic profiling and whole exome sequencing.
from pancreatic cancer. The hypothesis is that the tissue yield, as measured by tumor DNA and
cellular material is superior for Flexible Needle Biopsy (FNB) compared with conventional
Fine Needle Aspiration (FNA). Specifically, FNB will increase the proportion of cases in
which sufficient DNA is obtained to allow genomic profiling and whole exome sequencing.
This is a single-blinded randomized controlled trial with paired evaluation of conventional
FNA needle versus FNB needle stratified by lesion location (pancreas head tumor versus
pancreas body/tail). A minimum of 4 passes ( 2 with each needle) will be performed from all
the lesions. After each pass of needle, the on-site cytopathologists will evaluate the
adequacy and the degree of the pathological changes in the obtained material. Based on the
information provided by the onsite cytopathologists, the endosonographer will repeat the FNA
until enough histological material is obtained to confirm a diagnosis. Patients will be
assessed immediately after procedure and during the first 30 days with a follow-up.
FNA needle versus FNB needle stratified by lesion location (pancreas head tumor versus
pancreas body/tail). A minimum of 4 passes ( 2 with each needle) will be performed from all
the lesions. After each pass of needle, the on-site cytopathologists will evaluate the
adequacy and the degree of the pathological changes in the obtained material. Based on the
information provided by the onsite cytopathologists, the endosonographer will repeat the FNA
until enough histological material is obtained to confirm a diagnosis. Patients will be
assessed immediately after procedure and during the first 30 days with a follow-up.
Inclusion Criteria:
- Male and female patients who are 18 years old or older and are referred for the
evaluation of pancreatic mass lesion.
- International Normalized Ratio (INR) less than 1.5 and platelet count of more than
50,000.
- Medically stable to undergo sedation for EUS.
- Signed informed consent
Exclusion Criteria:
- Medical condition that preclude the patient from having a therapeutic procedure
regardless of the EUS finding
- Pregnant patients
We found this trial at
1
site
Mayo Clinic Mayo Clinic's campus in Arizona provides medical care for thousands of people from...
Click here to add this to my saved trials
